FDA Approves $34,000 Postpartum Depression Treatment

The Food and Drug Administration (FDA) has approved the first drug specifically designed to treat parents with Postpartum Depression. Brexanolone will be sold as “Zulresso” by Sage Therapeutics, Inc. It is administered intravenously over the course of 60 hours with patients feeling relief from depressive symptoms, typically within 48 hours.

Postpartum Depression (PPD) affects the bond between a parent and child, with mothers being the most at risk for depression and thoughts about harming themselves or their baby.

Patients must be monitored during the 60 hours in a supervised healthcare facility due to the risks and side effects observed in the clinical studies: dizziness, headaches, nausea, excessive sedation or loss of consciousness.

According to Sage Therapeutics, the drug will likely go for about $7,450 a vial, which amounts to approximately $34,000 before discounts or insurance. This excludes the costs that come with staying in a medical center for a couple of days. The drug is expected to be available June 2019.

---

#RebelKultureMagazine#Zulresso #Brexanolone#postpartumdepression #medic#mom #dad #parents#newparent #depression#newtreatment #FDA